https://mindmedicinelaw.com/briefing/epa-s-proposed-snurs-may-impact-psychedelic-research-20260730-27293The Psychedelic Journalen2026-07-30T15:05:48.574182+00:00EPA's Proposed SNURs May Impact Psychedelic ResearchEPA, SNURs, psychedelic research, chemical substances, TSCA, regulatory compliance, manufacture, import, notification period, regulatory frameworkhttps://mindmedicinelaw.com/briefing/ketamine-s-role-in-post-amputation-pain-management-20260729-27414The Psychedelic Journalen2026-07-30T15:05:58.218615+00:00Ketamine's Role in Post-Amputation Pain Managementketamine infusions, postoperative pain management, opioid reduction, limb amputation, public health policy, NMDA receptor, opioid crisis, pain management protocols, clinical trials, ketamine side effectshttps://mindmedicinelaw.com/briefing/fda-reorganization-impacts-on-psychedelic-drug-approval-20260729-26961The Psychedelic Journalen2026-07-29T15:05:46.697012+00:00FDA Reorganization: Impacts on Psychedelic Drug ApprovalFDA reorganization, psychedelic drug approval, regulatory efficiency, clinical trials, drug evaluation, market entry, psychedelic research, FDA policy, drug approval timelineshttps://mindmedicinelaw.com/briefing/dea-s-new-data-collection-rule-for-psychedelics-implications-20260729-26960The Psychedelic Journalen2026-07-29T15:05:34.929423+00:00DEA's New Data Collection Rule for Psychedelics: ImplicationsDEA, suspicious orders, controlled substances, psychedelic compounds, regulatory compliance, market dynamics, operational practices, data collection, industry impacthttps://mindmedicinelaw.com/briefing/vet-students-psychedelic-attitudes-impact-therapy-outlook-20260728-27141The Psychedelic Journalen2026-07-29T22:05:52.782672+00:00Vet Students' Psychedelic Attitudes Impact Therapy Outlookveterinary medicine, psychedelic therapies, student attitudes, treatment expectations, educational impact, cognitive frameworkshttps://mindmedicinelaw.com/briefing/hepatic-safety-of-ketamine-and-esketamine-for-trd-patients-20260728-27190The Psychedelic Journalen2026-07-29T22:05:37.332493+00:00Hepatic Safety of Ketamine and Esketamine for TRD Patientsketamine, esketamine, treatment-resistant depression, hepatic safety, liver monitoring, clinical trials, mental health treatment, Mayo Clinic, subanesthetic doseshttps://mindmedicinelaw.com/briefing/neuroimmune-signaling-in-ketamine-and-psychedelic-antidepressant-response-20260728-27189The Psychedelic Journalen2026-07-29T22:05:28.268957+00:00Neuroimmune Signaling in Ketamine and Psychedelic Antidepressant Responseneuroimmune signaling, ketamine, psychedelics, antidepressant response, IL-15, MCP-1, cytokine ratios, treatment-resistant depression, biomarkers, clinical trialshttps://mindmedicinelaw.com/briefing/ssri-dynamics-in-ocd-a-new-model-for-treatment-response-20260727-27145The Psychedelic Journalen2026-07-30T15:06:06.834762+00:00SSRI Dynamics in OCD: A New Model for Treatment ResponseSSRI treatment, obsessive-compulsive disorder, bistable dynamics, clinical trials, individual response, treatment remission, neuroscience, pharmacokinetics, OCD model, treatment strategieshttps://mindmedicinelaw.com/briefing/cardiovascular-risks-of-sympathomimetic-drugs-implications-20260727-27161The Psychedelic Journalen2026-07-29T22:06:12.472828+00:00Cardiovascular Risks of Sympathomimetic Drugs: Implicationssympathomimetic drugs, cardiovascular risks, cocaine, amphetamines, clinical guidelines, toxicological testing, emergency department, catecholamine excess, myocardial toxicity, individualized treatmenthttps://mindmedicinelaw.com/briefing/ketamine-assisted-psychotherapy-for-depression-current-research-20260727-27142The Psychedelic Journalen2026-07-29T22:06:04.255782+00:00Ketamine-Assisted Psychotherapy for Depression: Current Researchketamine-assisted psychotherapy, depression treatment, randomized controlled trials, psychotherapy models, mental health research, cognitive behavioral therapy, treatment-resistant depression, clinical guidelines, psychotherapy integration, ketamine riskshttps://mindmedicinelaw.com/briefing/psychedelics-and-chronic-pain-mechanisms-and-barriers-20260727-27143The Psychedelic Journalen2026-07-29T22:05:43.544928+00:00Psychedelics and Chronic Pain: Mechanisms and Barrierspsychedelics, chronic pain, central nervous system, neuroplasticity, clinical trials, expectancy bias, analgesics, neuroscience, pain management, translational barriershttps://mindmedicinelaw.com/briefing/medicine-4-0-revolutionizing-access-in-psychedelics-20260727-26825The Psychedelic Journalen2026-07-29T15:05:55.370265+00:00Medicine 4.0: Revolutionizing Access in Psychedelicsmedicine 4.0, psychedelic research, equitable access, healthcare policy, regulatory frameworks, scientific knowledge, digital health technologies, public health inequalities, commercial incentives, structural obstructionshttps://mindmedicinelaw.com/briefing/chlorogenic-acid-s-effects-on-ketamine-induced-schizophrenia-in-rats-20260724-27480The Psychedelic Journalen2026-07-30T22:04:55.748468+00:00Chlorogenic Acid's Effects on Ketamine-Induced Schizophrenia in Ratschlorogenic acid, ketamine, schizophrenia, neuropsychiatric disorders, rats, BDNF expression, sex-dependent effects, dietary interventions, prefrontal cortex, behavioral changeshttps://mindmedicinelaw.com/briefing/social-hierarchy-influences-stress-and-ketamine-effects-in-mice-20260721-27534The Psychedelic Journalen2026-07-30T22:05:07.171327+00:00Social Hierarchy Influences Stress and Ketamine Effects in Micesocial hierarchy, stress response, ketamine treatment, psychiatric disorders, mice study, personalized medicine, transcriptional response, dominant individuals, chronic stress, behavioral alterations